PHARMAC

Pharmaceutical Management Agency

Media release

PHARMAC, AstraZeneca finalise agreement on goserelin

PHARMAC and AstraZeneca have finalised an agreement for the prostate and breast cancer drug goserelin (Zoladex).

The agreement will mean that people with prostate cancer and breast cancer will continue to have fully funded access to both goserelin and leuprorelin (Lucrin). Both drugs are approved to treat breast cancer, prostate cancer, endometriosis and precocious puberty.

PHARMAC Medical Director Dr Peter Moodie says he is pleased with the outcome of discussions with AstraZeneca that have resulted in patients being able to continue taking both goserelin and leuprorelin, while savings are maintained for taxpayers.

ENDS